Novartis India Awaits India High Court Decision On Fate Of Glivec Patent
This article was originally published in PharmAsia News
Novartis India faces a key March decision by India’s Supreme Court centered on its patent for cancer drug Glivec.
You may also be interested in...
Chi-Med’s surufatinib has come up trumps in a second trial in neuroendocrine tumors, after the monitoring committee recommended an early halt following achievement of its PFS target in the pancreatic setting.
Oncology R&D isn’t waning, but investment in neurology and psychiatry drug development are paying off in new drug approvals. Rapid growth in CDER non-malignant hematology approvals reflects longer, broader trend toward orphan drugs.
We clean out your Martin Luther King Day inbox so you don't have to.